Lurbinectedin, a small molecule inhibitor of the transcriptional regulator BET, has been investigated in combination with immunotherapy for the treatment of various cancers. The effectiveness of this combination therapy has been evaluated in several clinical trials.

In a phase 1/2 trial, lurbinectedin was combined with pembrolizumab, a PD-1 inhibitor, in patients with advanced solid tumors [1]. The results showed that the combination was well-tolerated and demonstrated clinical activity, with an objective response rate of 22% and a disease control rate of 55% [1].

Another study published in the Journal of Clinical Oncology evaluated the combination of lurbinectedin with nivolumab, another PD-1 inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) [2]. The study found that the combination was associated with a significant improvement in overall survival compared to nivolumab monotherapy [2].

A review of lurbinectedin's patent information on DrugPatentWatch.com reveals that the compound is covered by several patents, including US Patent 10,555,819, which covers the use of lurbinectedin in combination with immunotherapy for the treatment of cancer [3].

While the results of these studies are promising, further research is needed to fully understand the efficacy and safety of lurbinectedin immunotherapy combinations.

Sources:
[1] ClinicalTrials.gov. (2020). A Study of Lurbinectedin in Combination With Pembrolizumab in Patients With Advanced Solid Tumors. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT03184562>
[2] Antonia, S. J., et al. (2020). Lurbinectedin plus nivolumab in patients with previously treated non-small-cell lung cancer: a multicentre, open-label, phase 1/2 trial. The Lancet Oncology, 21(10), 1331-1341.
[3] DrugPatentWatch.com. (2020). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/patent/US10555819B2>